PreOS (Preeclampsia Open Study), a Multicenter, Prospective, Non-Interventional Study Evaluating the Influence of the sFlt-1/PlGF Ratio on Physician Decision-Making in Pregnant Women with Suspicion of Preeclampsia
2015; Thieme Medical Publishers (Germany); Volume: 75; Issue: 03 Linguagem: Inglês
10.1055/s-0035-1548683
ISSN2199-6989
AutoresHolger Stepan, Dietmar Schlembach, A Ramoni, Franz Bahlmann, R. van der Does, Diethelm Messinger, Wilma D.J. Verhagen-Kamerbeek, Manfred Reim, Martin Hund, E Klein,
Tópico(s)Birth, Development, and Health
ResumoPreeclampsia is a major cause of maternal, fetal and neonatal morbidity/mortality. Levels of serum sFlt-1 (soluble fms-like tyrosine kinase-1) are increased and levels of serum PlGF (placental growth factor) are decreased in pregnant women developing or having diagnosed preeclampsia/eclampsia/HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome. Measurement of the sFlt-1/PlGF ratio is used as additional tool in preeclampsia diagnosis. However, the utility of the sFlt-1/PlGF ratio in guiding physicians' surveillance and treatment decisions for patients with suspicion of preeclampsia has not yet been evaluated in routine clinical practice. PreOS assessed the influence of the sFlt-1/PlGF test result on physicians' clinical decision-making regarding hospitalization, treatment and monitoring of patients who were considered likely to develop preeclampsia.
Referência(s)